Postby Rock_Robster » Thu May 16, 2019 6:46 pm
Hi Connie, sorry it may be a silly question but has he been exposed to oxaliplatin (eg via FOLFOX) before? This is a common first-line, along with FOLFIRI. Depending on some other factors an anti-VEGF drug such as Avastin (bevacizumab) may also often be considered.
Given he has been on Erbitux I presume he doesn’t have a RAS mutation... do you happen to know his MSS status and/or tumour mutation burden (TMB)? This would be important for potential immunotherapy routes (eg Keytruda/Opdivo).
The folk at CoH should be all over this stuff though anyway. Best wishes to you both.
Rob
41M Australia
2018 Dx RC
G2 EMVI LVI, 4 liver mets
pT3N1aM1a Stage IVa MSS NRAS G13R
CEA 14>2>32>16>19>30>140>70
11/18 FOLFOX
3/19 Liver resection
5/19 Pelvic IMRT
7/19 ULAR
8/19 Liver met
8/19 FOLFOX, FOLFOXIRI, FOLFIRI
12/19 Liver resection
NED 2 years
11/21 Liver met, PALN, lung nodules
3/22 PVE, lymphadenectomy, liver SBRT
10/22 PALN SBRT
11/22 Liver mets, peri nodule. Xeloda+Bev
4/23 XELIRI+Bev
9/23 ATRIUM trial
12/23 Modified FOLFIRI+Bev
3/24 VAXINIA (CF33 + hNIS) trial